Get the Stockscreener App
2.31
3.12%
+0.07
Finch Therapeutics Group Inc stock is currently priced at $2.31, with a 24-hour trading volume of 1,826.
It has seen a +3.12% increased in the last 24 hours and a -6.10% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.26 pivot point. If it approaches the $2.36 resistance level, significant changes may occur.
Previous Close:
$2.24
Open:
$2.28
24h Volume:
1,826
Market Cap:
$3.71M
Revenue:
$614.00K
Net Income/Loss:
$-76.35M
P/E Ratio:
-0.0267
EPS:
-86.53
Net Cash Flow:
$-31.51M
1W Performance:
+3.12%
1M Performance:
-6.10%
6M Performance:
-37.31%
1Y Performance:
+492.76%
1D Range:
$2.28
$2.34
52W Range:
$0.2505
$16.74
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
Name
Finch Therapeutics Group Inc
Sector
Industry
Phone
617 229 6499
Address
200 Inner Belt Road, Suite 400, Somerville
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-22 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | BofA Securities | Buy |
| Apr-13-21 | Initiated | Evercore ISI | Outperform |
| Apr-13-21 | Initiated | Jefferies | Buy |
Finch Therapeutics Group Inc Stock (FNCH) Latest News
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Finch Therapeutics Group Inc Stock (FNCH) Financials Data
Finch Therapeutics Group Inc (FNCH) Revenue 2024
FNCH reported a revenue (TTM) of $614.00 thousand for the quarter ending March 31, 2023, a -96.00% decline year-over-year.
Finch Therapeutics Group Inc (FNCH) Net Income 2024
FNCH net income (TTM) was -$76.35 million for the quarter ending December 31, 2023, a +33.41% increase year-over-year.
Finch Therapeutics Group Inc (FNCH) Cash Flow 2024
FNCH recorded a free cash flow (TTM) of -$31.50 million for the quarter ending December 31, 2023, a +59.10% increase year-over-year.
Finch Therapeutics Group Inc (FNCH) Earnings per Share 2024
FNCH earnings per share (TTM) was -$47.63 for the quarter ending December 31, 2023, a +33.93% growth year-over-year.
Finch Therapeutics Group Inc Stock (FNCH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SMISEK JEFFERY A | Director |
Mar 28 '24 |
Sale |
2.61 |
1,600 |
4,176 |
6,512 |
| SMISEK JEFFERY A | Director |
Nov 22 '23 |
Sale |
3.64 |
1,470 |
5,351 |
6,642 |
| Graf Susan E | Director |
Jun 09 '23 |
Buy |
0.27 |
5,010 |
1,353 |
5,010 |
About Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
0.86%
3.21%
Cap:
|
Volume (24h):